1. Tarcin O, Yavuz DG, Ozben B, Telli A, Ogunc AV, Yuksel M, et al. Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects. J Clin Endocrinol Metab. 2009 Oct;94(10):4023-30.
2. Forman JP, Giovannucci E, Holmes MD, Bischoff-Ferrari HA, Tworoger SS, Willett WC, et al.
Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension. 2007 May;49(5):1063-9.
3. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008 Jan 29;117(4):503-11.
4. Lin C, Rajakumar A, Plymire DA, Verma V, Markovic N, Hubel CA. Maternal endothelial progenitor colony-forming units with macrophage characteristics are reduced in preeclampsia. Am J Hypertens. 2009 Sep;22(9):1014-9.
5. Chambers JC, Fusi L, Malik IS, Haskard DO, De Swiet M, Kooner JS. Association of maternal endothelial dysfunction with preeclampsia. JAMA. 2001 Mar 28;285(12):1607-12.
6. Bodnar LM, Catov JM, Simhan HN, Holick MF, Powers RW, Roberts JM. Maternal vitamin D deficiency increases the risk of preeclampsia. J Clin Endocrinol Metab. 2007 Sep;92(9):3517-22.
7. Wei SQ, Audibert F, Hidiroglou N, Sarafin K, Julien P, Wu Y, et al. Longitudinal vitamin D status in pregnancy and the risk of pre-eclampsia. BJOG. 2012 Jun;119(7):832-9.
8. Cooper JC, Sharkey AM, Charnock-Jones DS, Palmer CR, Smith SK. VEGF mRNA levels in placentae from pregnancies complicated by pre-eclampsia. Br J Obstet Gynaecol. 1996
Dec;103(12):1191-6.
9. Schnaper HW, Grant DS, Stetler-Stevenson WG, Fridman R, D'Orazi G, Murphy AN, et al. Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro. J Cell Physiol. 1993 Aug;156(2):235-46.
10. Barrett H, McElduff A. Vitamin D and pregnancy: An old problem revisited. Best Pract Res Clin Endocrinol Metab. 2010 Aug;24(4):527-39.
11. Mehta RG, Mehta RR. Vitamin D and cancer. J Nutr Biochem. 2002 May;13(5):252-64.
12. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol. 2005 Jul;289(1):F8-28.
13. Van Cromphaut SJ, Dewerchin M, Hoenderop JG, Stockmans I, Van Herck E, Kato S, et al.
Duodenal calcium absorption in vitamin D receptor-knockout mice: Functional and molecular aspects.
Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13324-9.
14. Tinkler SM, Linder JE, Williams DM, Johnson NW. Formation of osteoclasts from blood monocytes during 1 alpha-OH vit D-stimulated bone resorption in mice. J Anat. 1981 Oct;133(Pt 3):389-96.
15. Wang TT, Nestel FP, Bourdeau V, Nagai Y, Wang Q, Liao J, et al. Cutting edge:
1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol. 2004 Sep 1;173(5):2909-12.
23
16. Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J. 2005 Jul;19(9):1067-77.
17. Xie Z, Komuves L, Yu QC, Elalieh H, Ng DC, Leary C, et al. Lack of the vitamin D receptor is associated with reduced epidermal differentiation and hair follicle growth. J Invest Dermatol. 2002 Jan;118(1):11-6.
18. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002 Jul;110(2):229-38.
19. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: Results of a randomized trial. Am J Clin Nutr. 2007
Jun;85(6):1586-91.
20. Bertone-Johnson ER, Chen WY, Holick MF, Hollis BW, Colditz GA, Willett WC, et al. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1991-7.
21. Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr. 2004 May;79(5):820-5.
22. Nyomba BL, Bouillon R, De Moor P. Influence of vitamin D status on insulin secretion and glucose tolerance in the rabbit. Endocrinology. 1984 Jul;115(1):191-7.
23. Palomer X, Gonzalez-Clemente JM, Blanco-Vaca F, Mauricio D. Role of vitamin D in the pathogenesis of type 2 diabetes mellitus. Diabetes Obes Metab. 2008 Mar;10(3):185-97.
24. Hatun S, Ozkan B, Orbak Z, Doneray H, Cizmecioglu F, Toprak D, et al. Vitamin D deficiency in early infancy. J Nutr. 2005 Feb;135(2):279-82.
25. Holick MF. Vitamin D deficiency. N Engl J Med. 2007 Jul 19;357(3):266-81.
26. Burris HH, Rifas-Shiman SL, Camargo CA,Jr, Litonjua AA, Huh SY, Rich-Edwards JW, et al.
Plasma 25-hydroxyvitamin D during pregnancy and small-for-gestational age in black and white infants. Ann Epidemiol. 2012 Aug;22(8):581-6.
27. Shin JS, Choi MY, Longtine MS, Nelson DM. Vitamin D effects on pregnancy and the placenta.
Placenta. 2010 Dec;31(12):1027-34.
28. Zehnder D, Bland R, Chana RS, Wheeler DC, Howie AJ, Williams MC, et al. Synthesis of 1,25-dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: A novel autocrine determinant of vascular cell adhesion. J Am Soc Nephrol. 2002 Mar;13(3):621-9.
29. Zehnder D, Bland R, Williams MC, McNinch RW, Howie AJ, Stewart PM, et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab. 2001 Feb;86(2):888-94.
30. EFSA European Food Safety Authority. Tolerable upper intakes levels of vitamins and minerals.
EFSA Journal. 2006 Feb;92-9199-014-0.
31. Chapuy MC, Preziosi P, Maamer M, Arnaud S, Galan P, Hercberg S, et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int. 1997;7(5):439-43.
24
32. Holick MF, Siris ES, Binkley N, Beard MK, Khan A, Katzer JT, et al. Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab. 2005 Jun;90(6):3215-24.
33. Nesby-O'Dell S, Scanlon KS, Cogswell ME, Gillespie C, Hollis BW, Looker AC, et al.
Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988-1994. Am J Clin Nutr. 2002 Jul;76(1):187-92.
34. Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: Exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab. 1988 Aug;67(2):373-8.
35. Wagner CL, Greer FR, American Academy of Pediatrics Section on Breastfeeding, American Academy of Pediatrics Committee on Nutrition. Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. Pediatrics. 2008 Nov;122(5):1142-52.
36. Brooke OG, Brown IR, Bone CD, Carter ND, Cleeve HJ, Maxwell JD, et al. Vitamin D
supplements in pregnant Asian women: Effects on calcium status and fetal growth. Br Med J. 1980 Mar 15;280(6216):751-4.
37. Thomson K, Morley R, Grover SR, Zacharin MR. Postnatal evaluation of vitamin D and bone health in women who were vitamin D-deficient in pregnancy, and in their infants. Med J Aust. 2004 Nov 1;181(9):486-8.
38. Deutsche Gesellschaft für Ernährung. Referenzwerte für die Nährstoffzufuhr Vitamin D.
2012;978-3-86528-128-9.
39. Hur J, Yoon CH, Kim HS, Choi JH, Kang HJ, Hwang KK, et al. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol. 2004 Feb;24(2):288-93.
40. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997 Feb 14;275(5302):964-7.
41. Zhang ZG, Zhang L, Jiang Q, Chopp M. Bone marrow-derived endothelial progenitor cells participate in cerebral neovascularization after focal cerebral ischemia in the adult mouse. Circ Res.
2002 Feb 22;90(3):284-8.
42. George AL, Bangalore-Prakash P, Rajoria S, Suriano R, Shanmugam A, Mittelman A, et al.
Endothelial progenitor cell biology in disease and tissue regeneration. J Hematol Oncol. 2011 May 24;4:24,8722-4-24.
43. Gehling UM, Ergun S, Schumacher U, Wagener C, Pantel K, Otte M, et al. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood. 2000 May 15;95(10):3106-12.
44. Werner N, Junk S, Laufs U, Link A, Walenta K, Bohm M, et al. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ Res. 2003 Jul 25;93(2):e17-24.
45. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest. 2000 Jan;105(1):71-7.
25
46. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet.
1992 Nov 7;340(8828):1111-5.
47. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: A marker of atherosclerotic risk.
Arterioscler Thromb Vasc Biol. 2003 Feb 1;23(2):168-75.
48. Roberts JM. Preeclampsia: What we know and what we do not know. Semin Perinatol. 2000 Feb;24(1):24-8.
49. VanWijk MJ, Kublickiene K, Boer K, VanBavel E. Vascular function in preeclampsia. Cardiovasc Res. 2000 Jul;47(1):38-48.
50. Choi JH, Kim KL, Huh W, Kim B, Byun J, Suh W, et al. Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure. Arterioscler Thromb Vasc Biol. 2004 Jul;24(7):1246-52.
51. Fadini GP, Miorin M, Facco M, Bonamico S, Baesso I, Grego F, et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol. 2005 May 3;45(9):1449-57.
52. Jialal I, Devaraj S, Singh U, Huet BA. Decreased number and impaired functionality of endothelial progenitor cells in subjects with metabolic syndrome: Implications for increased cardiovascular risk.
Atherosclerosis. 2010 Jul;211(1):297-302.
53. Bozdag-Turan I, Turan RG, Paranskaya L, Arsoy NS, Turan CH, Akin I, et al. Correlation between the functional impairment of bone marrow-derived circulating progenitor cells and the extend of coronary artery disease. J Transl Med. 2012 Jul 9;10:143,5876-10-143.
54. Eizawa T, Ikeda U, Murakami Y, Matsui K, Yoshioka T, Takahashi M, et al. Decrease in circulating endothelial progenitor cells in patients with stable coronary artery disease. Heart. 2004 Jun;90(6):685-6.
55. Xia L, Zhou XP, Zhu JH, Xie XD, Zhang H, Wang XX, et al. Decrease and dysfunction of endothelial progenitor cells in umbilical cord blood with maternal pre-eclampsia. J Obstet Gynaecol Res. 2007 Aug;33(4):465-74.
56. Sugawara J, Mitsui-Saito M, Hayashi C, Hoshiai T, Senoo M, Chisaka H, et al. Decrease and senescence of endothelial progenitor cells in patients with preeclampsia. J Clin Endocrinol Metab.
2005 Sep;90(9):5329-32.
57. Hristov M, Erl W, Weber PC. Endothelial progenitor cells: Mobilization, differentiation, and homing. Arterioscler Thromb Vasc Biol. 2003 Jul 1;23(7):1185-9.
58. Khan SS, Solomon MA, McCoy JP,Jr. Detection of circulating endothelial cells and endothelial progenitor cells by flow cytometry. Cytometry B ClinCytom. 2005 Mar;64(1):1-8.
59. Llevadot J, Murasawa S, Kureishi Y, Uchida S, Masuda H, Kawamoto A, et al. HMG-CoA reductase inhibitor mobilizes bone marrow--derived endothelial progenitor cells. J Clin Invest. 2001 Aug;108(3):399-405.
26
60. Laufs U, Urhausen A, Werner N, Scharhag J, Heitz A, Kissner G, et al. Running exercise of different duration and intensity: Effect on endothelial progenitor cells in healthy subjects. Eur J Cardiovasc Prev Rehabil. 2005 Aug;12(4):407-14.
61. Iwakura A, Luedemann C, Shastry S, Hanley A, Kearney M, Aikawa R, et al. Estrogen-mediated, endothelial nitric oxide synthase-dependent mobilization of bone marrow-derived endothelial
progenitor cells contributes to reendothelialization after arterial injury. Circulation. 2003 Dec 23;108(25):3115-21.
62. George J, Shmilovich H, Deutsch V, Miller H, Keren G, Roth A. Comparative analysis of methods for assessment of circulating endothelial progenitor cells. Tissue Eng. 2006 Feb;12(2):331-5.
63. Rehman J, Li J, Orschell CM, March KL. Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation. 2003 Mar 4;107(8):1164-9.
64. Hirschi KK, Ingram DA, Yoder MC. Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler Thromb Vasc Biol. 2008 Sep;28(9):1584-95.
65. Urbich C, Dimmeler S. Endothelial progenitor cells: Characterization and role in vascular biology.
Circ Res. 2004 Aug 20;95(4):343-53.
66. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009 Jun;33(3):130-7.
67. AWMF Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften.
Diagnostik und Therapie hypertensiver Schwangerschaftserkrankungen. 2007;015/018.
68. Abi-Said D, Annegers JF, Combs-Cantrell D, Frankowski RF, Willmore LJ. Case-control study of the risk factors for eclampsia. Am J Epidemiol. 1995 Aug 15;142(4):437-41.
69. Stone JL, Lockwood CJ, Berkowitz GS, Alvarez M, Lapinski R, Berkowitz RL. Risk factors for severe preeclampsia. Obstet Gynecol. 1994 Mar;83(3):357-61.
70. Haugen M, Brantsaeter AL, Trogstad L, Alexander J, Roth C, Magnus P, et al. Vitamin D supplementation and reduced risk of preeclampsia in nulliparous women. Epidemiology. 2009 Sep;20(5):720-6.
71. Mattar F, Sibai BM. Eclampsia. VIII. risk factors for maternal morbidity. Am J Obstet Gynecol.
2000 Feb;182(2):307-12.
72. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010 Aug 21;376(9741):631-44.
73. Meekins JW, Pijnenborg R, Hanssens M, McFadyen IR, van Asshe A. A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br J Obstet Gynaecol. 1994 Aug;101(8):669-74.
74. Iruela-Arispe ML. Normal placentation: A tale that requires an epithelial-to-endothelial conversion.
J Clin Invest. 1997 May 1;99(9):2057-8.
75. Hu W, Wang H, Wang Z, Huang H, Dong M. Elevated serum levels of interleukin-15 and interleukin-16 in preeclampsia. J Reprod Immunol. 2007 Apr;73(2):166-71.
27
76. Saposnik B, Peynaud-Debayle E, Stepanian A, Baron G, Simansour M, Mandelbrot L, et al.
Elevated soluble endothelial cell protein C receptor (sEPCR) levels in women with preeclampsia: A marker of endothelial activation/damage? Thromb Res. 2012 Feb;129(2):152-7.
77. Johnson MR, Anim-Nyame N, Johnson P, Sooranna SR, Steer PJ. Does endothelial cell activation occur with intrauterine growth restriction? BJOG. 2002 Jul;109(7):836-9.
78. Clark BA, Ludmir J, Epstein FH, Alvarez J, Tavara L, Bazul J, et al. Urinary cyclic GMP, endothelin, and prostaglandin E2 in normal pregnancy and preeclampsia. Am J Perinatol. 1997 Oct;14(9):559-62.
79. Vainio M, Riutta A, Koivisto AM, Maenpaa J. Prostacyclin, thromboxane A and the effect of low-dose ASA in pregnancies at high risk for hypertensive disorders. Acta Obstet Gynecol Scand. 2004 Dec;83(12):1119-23.
80. Roberts JM, Lain KY. Recent insights into the pathogenesis of pre-eclampsia. Placenta. 2002 May;23(5):359-72.
81. Schobel HP, Fischer T, Heuszer K, Geiger H, Schmieder RE. Preeclampsia -- a state of sympathetic overactivity. N Engl J Med. 1996 Nov 14;335(20):1480-5.
82. Strevens H, Wide-Swensson D, Hansen A, Horn T, Ingemarsson I, Larsen S, et al. Glomerular endotheliosis in normal pregnancy and pre-eclampsia. BJOG. 2003 Sep;110(9):831-6.
83. Paternoster D, Stella A, Simioni P, Trovo S, Plebani P, Girolami A. Clotting inhibitors and fibronectin as potential markers in preeclampsia. Int J Gynaecol Obstet. 1994 Dec;47(3):215-21.
84. Grundmann M, Woywodt A, Kirsch T, Hollwitz B, Oehler K, Erdbruegger U, et al. Circulating endothelial cells: A marker of vascular damage in patients with preeclampsia. Am J Obstet Gynecol.
2008 Mar;198(3):317.e1,317.e5.
85. Bayliss H, Churchill D, Beevers M, Beevers DG. Anti-hypertensive drugs in pregnancy and fetal growth: Evidence for "pharmacological programming" in the first trimester? Hypertens Pregnancy.
2002;21(2):161-74.
86. Coetzee EJ, Dommisse J, Anthony J. A randomised controlled trial of intravenous magnesium sulphate versus placebo in the management of women with severe pre-eclampsia. Br J Obstet Gynaecol. 1998 Mar;105(3):300-3.
87. Martin AM, Bindra R, Curcio P, Cicero S, Nicolaides KH. Screening for pre-eclampsia and fetal growth restriction by uterine artery doppler at 11-14 weeks of gestation. Ultrasound Obstet Gynecol.
2001 Dec;18(6):583-6.
88. Teixeira PG, Cabral AC, Andrade SP, Reis ZS, da Cruz LP, Pereira JB, et al. Placental growth factor (PlGF) is a surrogate marker in preeclamptic hypertension. Hypertens Pregnancy.
2008;27(1):65-73.
89. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004 Feb 12;350(7):672-83.
90. Ahmad S, Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res. 2004 Oct 29;95(9):884-91.
28
91. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006 Sep 7;355(10):992-1005.
92. Foidart JM, Munaut C, Chantraine F, Akolekar R, Nicolaides KH. Maternal plasma soluble endoglin at 11-13 weeks' gestation in pre-eclampsia. Ultrasound Obstet Gynecol. 2010 Jun;35(6):680-7.
93. Sibai BM, Caritis SN, Thom E, Klebanoff M, McNellis D, Rocco L, et al. Prevention of
preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med.
1993 Oct 21;329(17):1213-8.
94. Doridot L, Passet B, Mehats C, Rigourd V, Barbaux S, Ducat A, et al. Preeclampsia-like
symptoms induced in mice by fetoplacental expression of STOX1 are reversed by aspirin treatment.
Hypertension. 2013 Mar;61(3):662-8.
95. Caritis S, Sibai B, Hauth J, Lindheimer MD, Klebanoff M, Thom E, et al. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human
Development Network of Maternal-Fetal Medicine Units. N Engl J Med. 1998 Mar 12;338(11):701-5.
96. Villa PM, Kajantie E, Raikkonen K, Pesonen AK, Hamalainen E, Vainio M, et al. Aspirin in the prevention of pre-eclampsia in high-risk women: A randomised placebo-controlled PREDO trial and a meta-analysis of randomised trials. BJOG. 2013 Jan;120(1):64-74.
97. Sugden JA, Davies JI, Witham MD, Morris AD, Struthers AD. Vitamin D improves endothelial function in patients with type 2 diabetes mellitus and low vitamin D levels. Diabet Med. 2008 Mar;25(3):320-5.
98. Talmor Y, Golan E, Benchetrit S, Bernheim J, Klein O, Green J, et al. Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells. Am J Physiol Renal Physiol. 2008 May;294(5):F1059-64.
99. Jablonski KL, Chonchol M, Pierce GL, Walker AE, Seals DR. 25-hydroxyvitamin D deficiency is associated with inflammation-linked vascular endothelial dysfunction in middle-aged and older adults.
Hypertension. 2011 Jan;57(1):63-9.
100. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: A double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2006 Apr;83(4):754-9.
101. Cardus A, Panizo S, Encinas M, Dolcet X, Gallego C, Aldea M, et al. 1,25-dihydroxyvitamin D3 regulates VEGF production through a vitamin D response element in the VEGF promoter.
Atherosclerosis. 2009 May;204(1):85-9.
102. Cardus A, Parisi E, Gallego C, Aldea M, Fernandez E, Valdivielso JM. 1,25-dihydroxyvitamin D3 stimulates vascular smooth muscle cell proliferation through a VEGF-mediated pathway. Kidney Int. 2006 Apr;69(8):1377-84.
103. Bills VL, Varet J, Millar A, Harper SJ, Soothill PW, Bates DO. Failure to up-regulate VEGF165b in maternal plasma is a first trimester predictive marker for pre-eclampsia. Clin Sci (Lond). 2009 Feb;116(3):265-72.
29
104. Pepper MS. Manipulating angiogenesis. from basic science to the bedside. Arterioscler Thromb Vasc Biol. 1997 Apr;17(4):605-19.
105. Bao BY, Yao J, Lee YF. 1alpha, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis. 2006 Sep;27(9):1883-93.
106. Shokravi MT, Marcus DM, Alroy J, Egan K, Saornil MA, Albert DM. Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma. Invest Ophthalmol Vis Sci. 1995 Jan;36(1):83-7.
107. Holt PR, Arber N, Halmos B, Forde K, Kissileff H, McGlynn KA, et al. Colonic epithelial cell proliferation decreases with increasing levels of serum 25-hydroxy vitamin D. Cancer Epidemiol Biomarkers Prev. 2002 Jan;11(1):113-9.
108. Fernandez-Patron C, Radomski MW, Davidge ST. Role of matrix metalloproteinase-2 in thrombin-induced vasorelaxation of rat mesenteric arteries. Am J Physiol Heart Circ Physiol. 2000 May;278(5):H1473-9.
109. Merchant SJ, Davidge ST. The role of matrix metalloproteinases in vascular function:
Implications for normal pregnancy and pre-eclampsia. BJOG. 2004 Sep;111(9):931-9.
110. Montagnana M, Lippi G, Albiero A, Scevarolli S, Salvagno GL, Franchi M, et al. Evaluation of metalloproteinases 2 and 9 and their inhibitors in physiologic and pre-eclamptic pregnancy. J Clin Lab Anal. 2009;23(2):88-92.
111. Baker PN, Davidge ST, Roberts JM. Plasma from women with preeclampsia increases endothelial cell nitric oxide production. Hypertension. 1995 Aug;26(2):244-8.
112. Wang H, Keiser JA. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: Role of flt-1. Circ Res. 1998 Oct 19;83(8):832-40.
113. Sipos PI, Crocker IP, Hubel CA, Baker PN. Endothelial progenitor cells: Their potential in the placental vasculature and related complications. Placenta. 2010 Jan;31(1):1-10.
114. Hollis BW, Johnson D, Hulsey TC, Ebeling M, Wagner CL. Vitamin D supplementation during pregnancy: Double-blind, randomized clinical trial of safety and effectiveness. J Bone Miner Res.
2011 Oct;26(10):2341-57.
115. Bahlmann FH, de Groot K, Mueller O, Hertel B, Haller H, Fliser D. Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension.
2005 March;45:526–529.
116. Abou-Saleh H, Yacoub D, Théorêt JF, Gillis MA, Neagoe PE, Labarthe B, et al. Endothelial progenitor cells bind and inhibit platelet function and thrombus formation. Circulation. 2009 December;120(22):2230–9.
31
8. Publikationen
Vorträge
25. Kongress der Deutschen Gesellschaft für Perinatale Medizin (Berlin 2011):
Vitamin D3 fördert das angiogene Potenzial von endothelialen Vorläuferzellen M. Haidar; M. Grundmann; F. von Versen-Höynck
18. World Congress International Society for the Study of Hypertension in Pregnancy (ISSHP) (Genf 2012): Vitamin D promotes endothelial progenitor cell differentiation in placental development via a VEGF-mediated pathway
M. Grundmann; M. Haidar; S. Haß; C.A. Hubel; F. von Versen-Höynck
Poster
Grundmann M; Haidar M; Hubel CA; von Versen-Höynck F. Vitamin D Enhances VEGF Expression in Endothelial Progenitor Cells. 59th Annual Meeting of the Society for Gynecologic Investigation 3/2012, San Diego, USA (Abstract
veröffentlicht in Reproductive Sciences Vol. 19 No. 3 (Supplement) March 2012
Veröffentlichung
“Vitamin D improves the angiogenic properties of endothelial progenitor cells”
Grundmann M*; Haidar M*; Placzko S; Niendorf R; Darashchonak N; Hubel CA;
von Versen-Höynck F (American Journal of Physiology – Cell Physiology; 2012 Nov;303(9):C954-62) (* shared first authorship)
32
9. Erklärung nach §2 Abs. 2 Nr. 6 und 7 PromO
Ich erkläre, dass ich die der Medizinischen Hochschule Hannover zur Promotion eingereichte Dissertation mit dem Titel „Vitamin D improves the angiogenic properties of endothelial progenitor cells“ in der Klinik für Frauenheilkunde und Geburtshilfe unter Betreuung von PD Dr. med. Frauke von Versen-Höynck in Zusammenarbeit mit Dr. med. Magdalena Grundmann ohne sonstige Hilfe durchgeführt und bei der Abfassung der Dissertation keine anderen als die dort aufgeführten Hilfsmittel benutzt habe.
Die Gelegenheit zum vorliegenden Promotionsverfahren ist mir nicht kommerziell vermittelt worden. Insbesondere habe ich keine Organisation eingeschaltet, die gegen Entgelt
Betreuerinnen und Betreuer für die Anfertigung von Dissertationen sucht oder die mir oben liegenden Pflichten hinsichtlich der Prüfungsleistungen für mich ganz oder teilweise erledigt.
Ich habe diese Dissertation bisher an keiner in- oder ausländischen Hochschule zur Promotion eingereicht. Weiterhin versichere ich, dass ich den beantragten Titel bisher noch nicht
erworben habe.
Ergebnisse der Dissertation wurden in folgendem Publikationsorgan veröffentlicht:
American Journal of Physiology – Cell Physiology.
Hannover, den 30.06.2014
_____________________
Mariam Haidar
33
10. Danksagung
Für die Unterstützung an meiner Promotionsarbeit verdienen sehr vielen Menschen einen herzlichen Dank. Besonders möchte ich mich bei meinen beiden Betreuerinnen Frau PD Dr.
med. Frauke von Versen-Höynck und Frau Dr. med. Magdalena Grundmann bedanken, denn sie gaben mir mit Ihrem Fachwissen, ihrer konstruktiven Kritik und ihren vielen Ideen immer
med. Frauke von Versen-Höynck und Frau Dr. med. Magdalena Grundmann bedanken, denn sie gaben mir mit Ihrem Fachwissen, ihrer konstruktiven Kritik und ihren vielen Ideen immer